AzTrials
AzTrials

Cushing's DiseaseMEMOCUSHNCT02603653

Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease

A study testing Virtual radial task in 3D in people with Cushing's Disease, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed the frequency of somatic sequelas and persistent alteration in quality of life despite the cure of the disease. Read more about this study

Who is it for?
Ages 18 to 60 yearsHealthy volunteers can take part
Conditions the study is for
Cushing's Disease
What is being tested?
Virtual radial task in 3D
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteFrance
Study dates
4 Feb 2016to 3 Aug 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients :
  • history of Cushing's Disease
  • aged : 18 - 60 years
  • Biological remission of Cushing's disease for at least one year
  • Affiliation to Social Security
  • Informed consent signed by patient and investigator (at the latest the inclusion's day, before study's exams)
Show all 10Show fewer
  • For controls :
  • People aged 18 to 60 years matched to patients for age, sex and educational level
  • Affiliation to Social Security
  • Informed consent signed by patient and investigator (at the latest the inclusion's day, before study's exams)

Who cannot join

  • For patients :
  • Persistent hypercortisolism (even mild)
  • Current treatment of hypercortisolism with drugs
  • Obesity (BMI >30 kg/m²)
  • Alcohol or drug addiction present or past
  • Growth hormone deficit
Show all 25Show fewer
  • Diabetes mellitus with hemoglobin A1c > 7.5% and/or fasting blood glucose > 1.4 g/L
  • History of pituitary radiotherapy
  • History of cerebrovascular or neuro-cerebral disease
  • untreated dysthyroidism
  • Current psychotropic drug treatment
  • Pregnancy
  • Use of glucocorticoids in the last 3 months before study (aside hydrocortisone replacement therapy)
  • Excessive hydrocortisone replacement therapy (unadjusted to weight and/or with evening administration)
  • For controls :
  • Obesity (BMI >30 kg/m²)
  • Alcohol or drug addiction present or past
  • Current psychotropic drug treatment
  • History of cerebrovascular or neuro-cerebral disease
  • Current pregnancy
  • Chronical use of corticoid (> 1 month), current or past
  • Use of glucocorticoids in the last 3 months before study (aside hydrocortisone replacement therapy)
  • Diabetes mellitus with hemoglobin A1c > 7.5% and/or fasting blood glucose > 1.4 g/L
  • Obesity (BMI >30 kg/m²)
  • untreated dysthyroidism

Trial locations and contacts

1 site in 1 country.

France1 site
  • Hôpital du Haut-Lévêque

    Pessac, 33604

Other trials in France

About this study

Official title: Cognitive Sequels of Cushing Syndrome

Cushing's disease is a state of chronic endogenous glucocorticoid excess. Cushing's disease is responsible for increased morbidity and mortality. Recent studies have pinpointed the frequency of somatic sequelas and persistent alteration in quality of life despite the cure of the disease. More specifically, a few studies have described persistent psychopathology, maladaptive personality and cognitive impairments in patients with a history of Cushing's disease. Among these, hippocampal memory deficits have been found in the majority of studies, a finding that is consistent with the alterations described in hippocampal neurons during chronic exposure to glucocorticoids. However, the tools currently available to assess hippocampal-dependent memory are multiple, sometimes difficult to perform by clinicians and to analyze or may lack of diagnostic sensitivity. The investigators have recently developed an original tool, the virtual radial task in 3D, which has shown to be reliable to detect subtle alterations in hippocampal-dependent memory in several human diseases. The primary aim of the study is the evaluation of persistent cognitive impairments (hippocampal memory) in patients cured of Cushing's disease for at least one year using the virtual radial task in 3D and to compare it with that obtained with classical cognitive tests.

Being tested
Virtual radial task in 3D
Medical subject headings
Pituitary ACTH Hypersecretion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Virtual radial task in 3DDevice

    The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.

Study groups in NCT02603653
Study groupRoleWhat they receive
PatientsExperimentalVirtual radial task in 3D
Receives: Device: Virtual radial task in 3D
ControlsExperimentalVirtual radial task in 3D
Receives: Device: Virtual radial task in 3D

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of right answers at virtual radial task in 3D

    Comparison of right answers in patients cured of Cushing's disease and in controls.

    Measured: baseline

Secondary outcomes (6)
  1. General Quality of life

    Comparison of quality of life of patients and controls with validated general questionnaire : SF-36 (SF for Short Form health survey)

    Measured: baseline

  2. Specific Quality of life for Cushing's Disease

    Comparison of quality of life of patients and controls with validated specific questionnaire for Cushing's Disease : Cushing-QoL

    Measured: baseline

  3. Number of participants with anxiety

    Evaluation of anxiety in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)

    Measured: baseline

  4. Number of participants with depression with MADRS

    Evaluation of depression in the two groups with Montgomery and Asberg Depression Rating Scale (MADRS) (questionnaire)

    Measured: baseline

  5. Number of participants with depression with HADS

    Evaluation of depression in the two groups with Hospital Anxiety and Depression Scale (HADS) scale (questionnaire)

    Measured: baseline

  6. Intensity of Cushing's syndrome

    Intensity of Cushing's disease will be evaluated with mean of free urinary cortisol. Hypothesis : intensity of hypercortisolism is correlated with sequels after cure.

    Measured: baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2015 (estimated)
  2. Study start4 Feb 2016
  3. Primary completion12 Feb 2017
  4. Study completion3 Aug 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02603653
Sponsor's protocol ID
C15-02
Other IDs
IDRCB
Acronym
MEMOCUSH
Status last verified
Nov 2015
First submitted
3 Nov 2015
Last updated
4 Dec 2025
Results posted
No
Data monitoring committee
No

Publications

  • Pupier E, Santos A, Etchamendy N, Lavielle A, Ferriere A, Marighetto A, Resmini E, Cota D, Webb SM, Tabarin A. Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing's disease in remission. Front Endocrinol (Lausanne). 2022 Aug 8;13:934347. doi: 10.3389/fendo.2022.934347. eCollection 2022.

    PubMed 36004342

Questions about this trial

What is this clinical trial studying?

A study testing Virtual radial task in 3D in people with Cushing's Disease, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of right answers at virtual radial task in 3D (time frame: baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02603653, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in